Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials

The Lancet

Volumn 392, Issue 10145, 2018, Pages 387-399

  Rothwell, Peter M ^a   Cook, Nancy R ^b,c   Gaziano, J Michael ^c   Price, Jacqueline F ^d   Belch, Jill F F ^e   Roncaglioni, Maria Carla ^f   Morimoto, Takeshi ^g   Mehta, Ziyah ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF DUNDEE   (United Kingdom)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^g HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CASE FATALITY RATE; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HAZARD RATIO; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY PREVENTION; SEX DIFFERENCE; SUDDEN DEATH; AGE; COLORECTAL TUMOR; KAPLAN MEIER METHOD; MORTALITY; PREVENTION AND CONTROL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX FACTOR; STATISTICS AND NUMERICAL DATA;

AGE FACTORS; AGED; ASPIRIN; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; DEATH, SUDDEN; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEX FACTORS; STROKE;

EID: 85051725634     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)31133-4     Document Type: Article

References (46)

1. Patrono, C, The multifaceted clinical readouts of platelet inhibition by low-dose aspirin. J Am Coll Cardiol 66 (2015), 74–85.
2. Bibbins-Domingo, K, Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med 164 (2016), 836–845.
3. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373 (2009), 1849–1860.
4. Basili, S, Pacini, G, Guagnano, MT, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48 (2006), 2531–2538.
5. Patrono, C, Rocca, B, Type 2 diabetes, obesity, and aspirin responsiveness. J Am Coll Cardiol 69 (2017), 613–615.
6. Schrör, K, Acetylsalicylic acid. 2nd edn., 2016, Wiley-VCH, Weinheim.
7. Giaretta, A, Rocca, B, Di Camillo, B, Toffolo, GM, Patrono, C, In silico modeling of the antiplatelet pharmacodynamics of low-dose aspirin in health and disease. Clin Pharmacol Ther 102 (2017), 823–831.
8. Clarke, RJ, Mayo, G, Price, P, FitzGerald, GA, Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 325 (1991), 1137–1141.
9. Berger, JS, Roncaglioni, MC, Avanzini, F, Pangrazzi, I, Tognoni, G, Brown, DL, Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295 (2006), 306–313.
10. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 299 (1978), 53–59.
11. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002), 71–86.
12. Rothwell, PM, Wilson, M, Elwin, CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376 (2010), 1741–1750.
13. Rothwell, PM, Fowkes, GR, Belch, JJ, Ogawa, H, Warlow, CP, Meade, TW, Long-term effect of aspirin on deaths due to cancer: pooled analysis of data from randomised controlled trials. Lancet 377 (2011), 31–41.
14. Rothwell, PM, Algra, A, Chen, Z, Diener, HC, Norrving, B, Mehta, Z, Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 388 (2016), 365–375.
15. Peto, R, Gray, R, Collins, R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 296 (1988), 313–316.
16. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321 (1989), 129–135.
17. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 351 (1998), 233–241.
18. Ridker, PM, Cook, NR, Lee, IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352 (2005), 1293–1304.
19. Belch, J, MacCuish, A, Campbell, I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ, 337, 2008, a1840.
20. Fowkes, FG, Price, JF, Stewart, MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303 (2010), 841–848.
21. Stürmer, T, Glynn, RJ, Lee, IM, Manson, JE, Buring, JE, Hennekens, CH, Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med 128 (1998), 713–720.
22. Cook, NR, Lee, IM, Gaziano, JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294 (2005), 47–55.
23. Cook, NR, Cole, SR, Hennekens, CH, Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. Am J Epidemiol 155 (2002), 1045–1053.
24. Hansson, L, Zanchetti, A, Carruthers, SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351 (1998), 1755–1762.
25. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 357 (2001), 89–95.
26. Ogawa, H, Nakayama, M, Morimoto, T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300 (2008), 2134–2141.
27. Ikeda, Y, Shimada, K, Teramoto, T, et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA 312 (2014), 2510–2520.
28. ESPS 2 Group, European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci 151:suppl (1997), S1–S77.
29. Farrell, B, Godwin, J, Richards, S, Warlow, C, The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991), 1044–1054.
30. European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 342 (1993), 1255–1262.
31. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325 (1991), 1261–1266.
32. SALT Collaborative Group. Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338 (1991), 1345–1349.
33. Maree, AO, Curtin, RJ, Dooley, M, et al. Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol 46 (2005), 1258–1263.
34. Boutaud, O, Sosa, IR, Amin, T, et al. Inhibition of the biosynthesis of prostaglandin E2 by low-dose aspirin: implications for adenocarcinoma metastasis. Cancer Prev Res 9 (2016), 855–865.
35. Hennekens, CH, Schneider, WR, Pokov, A, et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther 15 (2010), 344–348.
36. Hetzel, S, DeMets, D, Schneider, R, et al. Aspirin increases nitric oxide formation in chronic stable coronary disease. J Cardiovasc Pharmacol Ther 18 (2013), 217–221.
37. Juul-Moller, S, Edvardsson, N, Jahnmatz, B, Rosen, A, Srensen, S, Omblus, R, Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 340 (1992), 1421–1425.
38. Erlinge, D, Ten Berg, J, Foley, D, et al. Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol 60 (2012), 2032–2040.
39. Mahaffey, KW, Wojdyla, DM, Carroll, K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 124 (2011), 544–554.
40. Li, L, Geraghty, OC, Mehta, Z, Rothwell, PM, Age-specific risks, severity, time-course and outcome of bleeding on long-term antiplatelet treatment after vascular events: population-based cohort study. Lancet 390 (2017), 490–499.
41. Rothwell, PM, Price, JF, Fowkes, FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379 (2012), 1602–1612.
42. Hardie, DG, Molecular pathways: is AMPK a friend or a foe in cancer?. Clin Cancer Res 21 (2015), 3836–3840.
43. Colwell, JA, Bingham, SF, Abraira, C, et al. V.A. Cooperative Study of antiplatelet agents in diabetic patients after amputation for gangrene: unobserved, sudden, and unexpected deaths. J Diabet Complications 3 (1989), 191–197.
44. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 268 (1992), 1292–1300.
45. Cavalca, V, Rocca, B, Squellerio, I, et al. In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. Thromb Haemost 112 (2014), 118–127.
46. Capodanno, D, Patel, A, Dharmashankar, K, et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 4 (2011), 180–187.